40
Participants
Start Date
January 1, 2024
Primary Completion Date
April 30, 2025
Study Completion Date
February 28, 2026
Prograf
Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
Envarsus
Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
Toronto General Hospital, Toronto
Collaborators (1)
Paladin Labs Inc.
OTHER
University Health Network, Toronto
OTHER